KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, Christoph Zielinski, Manuel Ruiz-Borrego, Eva María Ciruelos, Montserrat Muñoz, Mireia Margelí, Begoña Bermejo, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, José Luis Alonso-Romero, José Ángel García-Saenz, Pedro Sánchez-Rovira, Elena Álvarez, José Ignacio Chacón, Santiago González-Santiago, César A Rodríguez, Sonia Servitja, Adam D Pfefferle, Jesús Herranz, Yuan Liu, Lisa A Carey, Isabel Romero-Camarero, Rosalía Caballero, Ángel Guerrero-Zotano, Charles M Perou, Miguel Martín

JCO Precis Oncol 9 e2400937

PMID40632974
PMCIDPMC12261110
DOI10.1200/PO-24-00937
发表日期2025-07-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: For hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC), first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is the standard of care. They are also used after progression on first-line aromatase inhibitors (AIs), but some patients may respond better to chemotherapy-based options. We examined tumor features associated with survival from GEICAM/2013-02 PEARL, a phase III trial of palbociclib + ET versus capecitabine in AI-resistant HR+/HER2- MBC. METHODS: For 158 and 155 patients from each arm, 878 previously published gene expression signatures were derived using RNA sequencing on pretreatment tumor specimens, both primary and metastatic. Multivariable Cox models for progression-free survival (PFS) and overall survival (OS) were constructed with 16 preselected signatures related to proliferation, loss of retinoblastoma, and immune infiltration, and via Elastic Net using all signatures. RESULTS: Significant PFS difference by PAM50 intrinsic subtype was observed with palbociclib + ET. Comparing treatment arms, luminal A subtype trended toward longer PFS with palbociclib + ET, and luminal B and nonluminal subtypes had significantly longer PFS with capecitabine. Three B-cell (B-lymphocyte)-associated signatures correlated with shorter OS with palbociclib + ET. The immune-activated Immune1 TCGA breast cancer signature had significant treatment arm interaction for OS. Elastic Net iteratively selected B-cell-associated signatures independently associated with shorter OS with palbociclib + ET. CONCLUSION: PAM50 intrinsic subtype predicted PFS differences between palbociclib + ET and capecitabine. Lower B-cell-associated gene expression predicted longer OS with palbociclib + ET versus capecitabine. These features may help identify HR+/HER2- tumors resistant to further ET-based treatment with CDK4/6i.

KM 提取结果

2 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure4 个面板

FIG 1.

FIG 1. PAM50 intrinsic subtype correlations with PFS and OS for each treatment arm. (A) Kaplan-Meier plot of PFS with palbociclib + ET by PAM50 luminal status. (B) Kaplan-Meier plot of PFS with capecitabine by PAM50 luminal status. (C) Kaplan-Meier plot of OS with palbociclib + ET by PAM50 luminal status. (D) Kaplan-Meier plot of OS with capecitabine by PAM50 luminal status. (E) Forest plot of PAM50 intrinsic subtype correlation with PFS between treatment arms. HRs compare PFS between treatment arms by PAM50 intrinsic subtype. Luminal B and nonluminal subtypes were significantly associated with longer PFS with capecitabine than with palbociclib + ET. ET, endocrine therapy; HR, hazard ratio; LumA, Luminal A; LumB, Luminal B; mOS, median overall survival; mPFS, median progression-free survival; Nonlum, Nonluminal; OS, overall survival; PFS, progression-free survival.

A

PFS

FIG 1. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
B

PFS

FIG 1. · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

FIG 1. · Panel C

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel C 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIG 1. · Panel D

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel D 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIG 4.

FIG 4. Kaplan-Meier plot of OS for patients treated with palbociclib + ET versus capecitabine by Immune1 TCGA breast cancer (TCGA_BRCA_1198_Immune1) signature expression. Survival curves are separated by low or high tumor expression (with respect to the median; solid or dotted) of the Immune1 TCGA breast cancer signature, and by treatment with palbociclib + ET or capecitabine (blue or red). ET, endocrine therapy; OS, overall survival; TCGA, The Cancer Genome Atlas.

OS

OS

FIG 4. · Panel OS

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel OS 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 2.FIG 2. Forest plots for HRs for PFS for each treatment arm for 16 selected biomarker signatures. (A) Adjusted HRs for PFS for patients treated with palbociclib + ET. (B) Adjusted HRs for PFS for patients treated with capecitabine. ET, endocrine therapy; HR, hazard ratio; PFS, progression-free survival; TCGA, The Cancer Genome Atlas.
非 KM Figure
FIG 3.FIG 3. Forest plots for HRs for OS for each treatment arm for 16 selected biomarker signatures. (A) Adjusted HRs for OS for patients treated with palbociclib + ET. (B) Adjusted HRs for OS for patients treated with capecitabine. ET, endocrine therapy; HR, hazard ratio; OS, overall survival; TCGA, The Cancer Genome Atlas.
非 KM Figure
FIG 5.FIG 5. Most frequently selected gene expression signatures in multivariable Cox models for survival with palbociclib + ET. Models based on gene expression signatures were iteratively constructed for all patients treated with palbociclib + ET, as well as patients with luminal A or B tumors only, via high-dimensional modeling using Elastic Net regression. Bar length represents frequency with which each signature was included in a constructed model. Signatures whose values positively correlated with survival are highlighted in green, and those whose values negatively correlated with survival are highlighted in red. (A) Most frequently selected signatures for models for PFS with palbociclib + ET. (B) Most frequently selected signatures in models for OS with palbociclib + ET. ET, endocrine therapy; HCI, Harrell C-index; OS, overall survival; PFS, progression-free survival; TCGA, The Cancer Genome Atlas.
非 KM Figure
FIG A1.FIG A1. CONSORT diagram of the study. ET, endocrine therapy.
非 KM Figure
FIG A2.FIG A2. Most frequently selected gene expression signatures in multivariable Cox models for survival with capecitabine. Models based on gene expression signatures were iteratively constructed for all patients treated with capecitabine, as well as patients with luminal A or B tumors only, via high-dimensional modeling using Elastic Net regression. Bar length represents frequency with which each signature was included in a constructed model. Signatures whose values positively correlated with survival are highlighted in green, and those whose values negatively correlated with survival are highlighted in red. (A) Most frequently selected signatures for models for PFS with capecitabine. (B) Most frequently selected signatures in models for OS with capecitabine. corr, correlation; HCI, Harrell C-index; OS, overall survival; PFS, progression-free survival; TCGA, The Cancer Genome Atlas.
非 KM Figure